

## **HESI Committee on Emerging Systems Toxicology for Assessment of Risk**

## **Annual Meeting**



**Register Here:** https://hesiglobal.org/estar-am2022/

Thursday November 3 <sup>rd</sup> (US Eastern Time)		
10:00 – 10:10 am	Welcome and Logistics	Ms. Connie Mitchell and Dr. Saddef Haq (HESI)
10:10 – 10:40 am	Meeting Objectives	Dr. Brian Chorley (US EPA), Dr. Deidre Dalmas Wilk (GSK)
10:40 – 11:30 am	Keynote #1 Progress in (metabol)omics-based chemical grouping	Dr. Mark Viant, (Michabo Health Science and University of Birmingham)
11:30 am – 1:00 pm	Review Existing Portfolio with Reports to Committee     Presentations to include overview of project goals, status, and achievements since last meeting.     Presentations to highlight key next steps, key questions or challenges anticipated in coming year (technical or logistical) and new/emerging opportunities for engagement on the project.	
11:30 am	— microRNA Biomarkers	Dr. Peter Yuen (NIH), Dr. Tatiana Sharipova (AbbVie)
12:00 pm	TgX DDI Biomarker Qualification	Dr. Henghong Li (Georgetown University)
12:30 pm	Transcriptomic POD	Dr. Jessica LaRocca (Corteva), Dr. Scott Auerbach (NIEHS)
1:00 – 1:20 pm	BREAK	
1:20 – 2:20 pm	Carcinogenomics Project	Dr. Chris Corton (US EPA), Dr. Keith Tanis (Merck)
2:20 – 3:10 pm	Keynote #2 Understanding Cell Biology and Toxicology with Spatial Transcriptomics: use Cases and Bioinformatic Platforms	Dr. Ali Ebrahimi, (GSK)
3:10 – 3:30 pm	Wrap-Up and Format for Day 2	

Friday November 4 <sup>th</sup> (US Eastern Time)			
10:00 – 10:10 am	Welcome, Logistics, Day 1 recap	Ms. Connie Mitchell and Dr. Saddef Haq (HESI)	
10:10 – 10:25 am	Cell Painting Updates	Dr. David Rouquie (Bayer)	
10:25 – 10:40 am	Error Corrected Sequencing	Dr. Patricia Escobar (Merck)	
10:40 am – 2:30 pm	Breakout Discussion for Error Corrected Sequencing or Cell Painting		
2:30 – 3:30 pm	Report Outs from Working Groups & Discussion – key decisions, proposed next steps, areas for team feedback		
3:30 – 4:00 pm	Reflection on Projects Presented and Future Directions  • Additional technical areas to be pursued?  • Outreach and recruitment?  • Funding, labor, bandwidth, and capacity considerations?  • Additional Grants to look into?  • Other?		
4 pm	Adjourn		